iKang Healthcare Group, Inc. Form SC 13D/A September 04, 2018

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **SCHEDULE 13D/A**

Under Securities Exchange Act of 1934 (Amendment No. 9)\*

# iKang Healthcare Group, Inc.

(Name of Issuer)

Class A Common Shares, par value US\$0.01 per share\*\*

(Title of Class of Securities)

45174L108\*\*\*

(CUSIP Number)

Mr. Lee Ligang Zhang

c/o iKang Healthcare Group, Inc.

B-6F Shimao Tower, 92A Jianguo Road

**Chaoyang District** 

**Beijing 100022** 

People s Republic of China

+86 10 5320 6688

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

#### August 24, 2018

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box o.

<i>Note.</i> Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. <i>See</i> Rule §240.13d-7(b) for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
** Not for trading, but only in connection with the registration of American Depositary Shares each representing 1/2 Class A Common Share.
*** This CUSIP applies to the American Depositary Shares, each representing 1/2 Class A Common Share.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i> ).

CUSIP No.	45174L108	13D/A				
1	Na	ne of Reporting Persons				
	I.F	I.R.S. Identification Nos. of Above Persons (Entities Only)				
		Ligang Zhang				
2		ck the Appropriate Box if a Member of a Group				
	(a)	0				
_	(b)	0				
3		C Use Only				
4	So	rce of Funds				
	O					
5	Ch	ck Box if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o				
6		Citizenship or Place of Organization				
		People s Republic of China				
	10	7 Sole Voting Power				
Number of		4,874,3711				
Shares		8 Shared Voting Power				
Beneficially		o Shared voting Power				
Owned by		· · · · · · · · · · · · · · · · · · ·				
Each		9 Sole Dispositive Power 4,874,3711				
Reporting		10 Shared Dispositive Power				
Person With	1	0				
11		Aggregate Amount Beneficially Owned by Each Reporting Person 4.874,3711				
12	2 Ch	ck Box if the Aggregate Amount in Row (11) Excludes Certain Shares o				
13		Percent of Class Represented by Amount in Row (11)				
13		13.6%.2 The voting power of the shares beneficially owned by the Reporting Person represents 34.3% of the total				
		outstanding voting power of all Common Shares.				
14		e of Reporting Person				
	IN					

The rights of the holders of Class A and Class C Common Shares are identical, except with respect to voting and conversion rights. Each Class A Common Share will be entitled to one vote per share. Each Class C Common Share will be entitled to 15 votes per share and is convertible at any time into one Class A Common Share.

2 Percentage calculated based on (i) 34,308,093 Class A Common Shares (excluding Class A Common Shares issued to the depositary and reserved for exercise of options) and 805,100 Class C Common Shares outstanding as of July 16, 2018, and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. and 500,000 Class A Common Shares issuable upon exercise of options held by Mr. Lee Ligang Zhang, in each case, within 60 days of the date of this Amendment No. 9.

<sup>1</sup> Consists of (i) 526,721 Class A Common Shares held by Time Intelligent Finance Limited; (ii) 805,100 Class C Common Shares held by Time Intelligent Finance Limited; (iii) 2,264,140 Class A Common Shares and 1,256,820 American Depositary Shares (representing 628,410 Class A Common Shares) held by ShanghaiMed, Inc., which is wholly owned by Time Intelligent Finance Limited; (iv) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9; and (v) 500,000 Class A Common Shares issuable upon exercise of options held by Mr. Lee Ligang Zhang within 60 days of the date of this Amendment No. 9.

CUSIP No.	45174L	108	13D/A				
1		Name of Reporting Pers	sons				
		I.R.S. Identification Nos. of Above Persons (Entities Only)					
		Time Intelligent Finan	nce Limited				
2		Check the Appropriate	Box if a Member of a Group				
		(a)	0				
		(b)	0				
3		SEC Use Only					
4		Source of Funds					
		00					
5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o						
6		Citizenship or Place of					
		British Virgin Islands					
		7	Sole Voting Power				
Number of			0				
Shares		8	Shared Voting Power				
Beneficially		Ü	4,374,3711				
Owned by		9	Sole Dispositive Power				
Each		9	0				
Reporting		10	Shared Dispositive Power				
Person With	1	10	4,374,3711				
11	1	A compacts A mayor Dan	· ·				
11	I	Aggregate Amount Beneficially Owned by Each Reporting Person					
1.0	_	4,374,3711					
12		Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares o					
13	3		sented by Amount in Row (11)				
		12.4%.2 The voting power of the shares beneficially owned by the Reporting Person represents 33.6% of the total					
			wer of all Common Shares.				
14	4	Type of Reporting Person	on .				
		CO					

<sup>1</sup> Consists of (i) 526,721 Class A Common Shares held by Time Intelligent Finance Limited; (ii) 805,100 Class C Common Shares held by Time Intelligent Finance Limited; (iii) 2,264,140 Class A Common Shares and 1,256,820 American Depositary Shares (representing 628,410 Class A Common Shares) held by ShanghaiMed, Inc.; and (iv) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9. As Time Intelligent Finance Limited is wholly owned by Time Evergreen Company Limited, which in turn is wholly owned by TMF (Cayman) Ltd. as trustee of Zhang s Family Trust with Mr. Lee Ligang Zhang as settlor, Time Intelligent Finance Limited shares the voting and dispositive power of such 4,374,371 Common Shares with Time Evergreen Company Limited and TMF (Cayman) Ltd.

<sup>2</sup> Percentage calculated based on (i) 34,308,093 Class A Common Shares (excluding Class A Common Shares issued to the depositary and reserved for exercise of options) and 805,100 Class C Common Shares outstanding as of July 16, 2018, and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9.

CUSIP No. 8	31783J 101	13D/A			
1	Name of Reporting Pe				
	I.R.S. Identification N	R.S. Identification Nos. of Above Persons (Entities Only)			
	ShanghaiMed, Inc.				
2	Check the Appropriate	e Box if a Member of a Group			
	(a)	0			
	(b) SEC Use Only	0			
3					
4	Source of Funds	Source of Funds			
	00				
5 Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o					
6	Citizenship or Place of	Citizenship or Place of Organization			
	British Virgin Islands				
	7	Sole Voting Power			
Number of		0			
Shares	8	Shared Voting Power			
Beneficially		3,042,5501			
Owned by	9	Sole Dispositive Power			
Each		0			
Reporting	10	Shared Dispositive Power			
Person With		3,042,5501			
11	Aggregate Amount Beneficially Owned by Each Reporting Person				
	3,042,5501				
12	Check Box if the Agg	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares o			
13		Percent of Class Represented by Amount in Row (11)			
		8.6%2. The voting power of the shares beneficially owned by the Reporting Person represents 6.5% of the total			
	outstanding voting power of all Common Shares.				
14		Type of Reporting Person			
	CO				

<sup>1</sup> Consists of (i) 2,264,140 Class A Common Shares and 1,256,820 American Depositary Shares (representing 628,410 Class A Common Shares) held by ShanghaiMed, Inc.; and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9. As ShanghaiMed, Inc. is wholly owned by Time Intelligent Finance Limited, it shares the voting and dispositive power of such 3,042,550 Common Shares with Time Intelligent Finance Limited, Time Evergreen Company Limited and TMF (Cayman) Ltd.

<sup>2</sup> Percentage calculated based on (i) 34,308,093 Class A Common Shares (excluding Class A Common Shares issued to the depositary and reserved for exercise of options) and 805,100 Class C Common Shares outstanding as of July 16, 2018, and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9.

13D/A

CUSIP No. 81783J 101

	1	Name of Reporti	ng Pers	ons	
		I.R.S. Identification Nos. of Above Persons (Entities Only)			
		TMF (Cayman)	Ltd. a	s the Trustee of Zhang s Family Trust	
	2	Check the Appro	priate I	Box if a Member of a Group	
		(a)		0	
		(b)		0	
	3	SEC Use Only			
	4	Source of Funds			
		00			
	5	Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o			
6	6	Citizenship or Pl			
		Cayman Islanda	s		
			7	Sole Voting Power	
Numbe	r of			0	
Shares			8	Shared Voting Power	
Benefic	•			4,374,3711	
Owned	by		9	Sole Dispositive Power	
Each				0	
Reporti Person			10	Shared Dispositive Power	
reison	W IIII			4,374,3711	
	11	Aggregate Amount Beneficially Owned by Each Reporting Person			
		4,374,3711			
	12	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares o			
	13	Percent of Class Represented by Amount in Row (11)			
		12.4%.2 The voting power of the shares beneficially owned by the Reporting Person represents 33.6% of the total			
				wer of all Common Shares.	
	14	Type of Reportin			
		CO	C		

<sup>1</sup> Consists of (i) 526,721 Class A Common Shares held by Time Intelligent Finance Limited; (ii) 805,100 Class C Common Shares held by Time Intelligent Finance Limited; (iii) 2,264,140 Class A Common Shares and 1,256,820 American Depositary Shares (representing 628,410 Class A Common Shares) held by ShanghaiMed, Inc.; and (iv) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9. TMF (Cayman) Ltd. is the trustee of Zhang s Family Trust with Mr. Lee Ligang Zhang as settlor. As TMF (Cayman) Ltd. holds all of the equity interests in Time Evergreen Company Limited which in turn holds all of the equity interests in Time Intelligent Finance Limited, TMF (Cayman) Ltd. shares the voting and dispositive power of such 4,374,371 Common Shares with Time Evergreen Company Limited and Time Intelligent Finance Limited.

<sup>2</sup> Percentage calculated based on (i) 34,308,093 Class A Common Shares (excluding Class A Common Shares issued to the depositary and reserved for exercise of options) and 805,100 Class C Common Shares outstanding as of July 16, 2018, and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9.

CUSIP No. 8	1783J 101	13D/A			
1	Name of Reporting	Persons			
	I.R.S. Identification	I.R.S. Identification Nos. of Above Persons (Entities Only)			
	Time Evergreen C	ompany Limited			
2	Check the Appropr	ate Box if a Member of a Group			
	(a)	0			
	(b)	0			
3	SEC Use Only				
4	Source of Funds				
	00				
5	osure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) o				
6		Citizenship or Place of Organization			
	British Virgin Isla	nds			
	7				
Number of		0			
Shares	8	•			
Beneficially	~	4,374,3711			
Owned by	9				
Each	7	0			
Reporting	10	v			
Person With	1,	1			
1.1	A A	4,374,3711			
11		Aggregate Amount Beneficially Owned by Each Reporting Person			
	4,374,3711				
12		Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares o			
13		presented by Amount in Row (11)			
		12.4%.2 The voting power of the shares beneficially owned by the Reporting Person represents 33.6% of the total			
		outstanding voting power of all Common Shares.			
14		Type of Reporting Person			
	CO	CO			

<sup>1</sup> Consists of (i) 526,721 Class A Common Shares held by Time Intelligent Finance Limited; (ii) 805,100 Class C Common Shares held by Time Intelligent Finance Limited; (iii) 2,264,140 Class A Common Shares and 1,256,820 American Depositary Shares (representing 628,410 Class A Common Shares) held by ShanghaiMed, Inc.; and (iv) 150,000 Class A Common Shares issuable to ShanghaiMed, Inc. upon its exercise of options within 60 days of the date of this Amendment No. 9. As Time Evergreen Company Limited holds all of the equity interests in Time Intelligent Finance Limited and is wholly owned by TMF (Cayman) Ltd. as trustee of Zhang s Family Trust with Mr. Lee Ligang Zhang as settlor, Time Evergreen Company shares the voting and dispositive power of such 4,374,371 Common Shares with Time Intelligent Finance Limited and TMF (Cayman) Ltd.

<sup>2</sup> Percentage calculated based on (i) 34,308,093 Class A Common Shares (excluding Class A Common Shares issued to the depositary and reserved for exercise of options) and 805,100 Class C Common Shares outstanding as of July 16, 2018, and (ii) 150,000 Class A Common Shares issuable upon exercise of options held by ShanghaiMed, Inc. within 60 days of the date of this Amendment No. 9.

#### **Introductory Note**

This Amendment No. 9 to Schedule 13D (this Amendment No. 9) amends and supplements the Schedule 13D filed jointly by the Reporting Persons with the Securities and Exchange Commission (the SEC) on September 9, 2015, as previously amended by Amendment No. 1 filed on January 5, 2016, Amendment No. 2 filed on June 7, 2016, Amendment No. 3 filed on August 25, 2017, and Amendment No. 4 filed on December 1, 2017, Amendment No. 5 filed on March 28, 2018, and Amendment No. 6 filed on March 28, 2018, Amendment No. 7 filed on April 24, 2018, and Amendment No. 8 filed on June 4, 2018, respectively (the Original Schedule 13D). Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have meanings as assigned thereto in the Original Schedule 13D unless defined herein.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer

Item 6 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

As previously disclosed by the Reporting Persons in Amendment No. 3 to their report on Schedule 13D filed on August 25, 2017 with the SEC, on August 25 2017, ShanghaiMed, Inc. ( **ShanghaiMed** ) entered into a Facility Agreement (as amended, the **Existing Facility Agreement** ), pursuant to which Gopher Global Credit Fund II ( **Gopher** ) provided loans to ShanghaiMed in an aggregate principal amount of US\$19,000,000. As previously disclosed by the Reporting Persons in Amendment No. 7 to Schedule 13D filed on April 24, 2018, ShanghaiMed made repayment of US\$8,000,000 under the Existing Facility Agreement as of April 6, 2018. Accordingly to the Existing Facility Agreement, ShanghaiMed was obligated to repay a portion of the outstanding amounts under the Existing Facility Agreement on August 24, 2018.

In order to refinance the amounts outstanding under the Existing Facility Agreement, ShanghaiMed entered into a Facility Agreement (the **New Facility Agreement**) with Gopher on August 24, 2018, pursuant to which Gopher provided a loan facility in the aggregate principal amount of US\$11,000,000 to ShanghaiMed. As required by the New Facility Agreement, on August 24, 2018, ShanghaiMed applied all the proceeds of the loan in the principal amount of \$11,000,000 that it utilized pursuant to the New Facility Agreement towards the repayment of the outstanding amounts under the Existing Facility Agreement (the **Repayment**).

Upon the Repayment, all of the securities of the Issuer held by ShanghaiMed and mortgaged in favor of Gopher to secure ShanghaiMed s obligations under the Existing Facility Agreement pursuant to the Equitable Mortgage over Shares, dated August 25, 2017, by and between ShanghaiMed and Gopher (the **Existing Share Mortgage** as amended by a Supplemental Deed dated November 29, 2017 and a Deed of Partial Release dated April 6, 2018), i.e., 792,317 Class A Common Shares, were released. In connection with such release, on August 24, 2018, ShanghaiMed entered into an equitable share mortgage (the **New Share Mortgage**) with Gopher in respect of an equal number of Class A Common Shares ( **New Mortgaged Shares**) held by ShanghaiMed to secure ShanghaiMed s obligations under the New Facility Agreement. ShanghaiMed may not, among other things, sell, transfer or otherwise dispose of any of the New Mortgaged Shares without the prior written consent of Gopher.

The New Share Mortgage will be immediately enforceable upon the occurrence of an event of default under the New Facility Agreement and delivery of an enforcement notice pursuant to the New Facility Agreement. In the event that the New Share Mortgage becomes enforceable, Gopher will be able to, among other things: (i) exercise all voting rights attaching to the New Mortgaged Shares under the New Share Mortgage, to receive and retain all dividends and other distributions made on or in respect of the New Mortgaged Shares, or to sell the New Mortgaged Shares as it may determine.

As previously disclosed by the Issuer in its reports on Form 6-K filed with the SEC on March 28, 2018 and on May 29, 2018, respectively, on March 26, 2018, the Issuer entered into an Agreement and Plan of Merger (as amended on May 29, 2018, the Merger Agreement ) with IK Healthcare Investment Limited ( Parent ), a special purpose vehicle wholly-owned by IK Healthcare Holdings Limited ( Holdco ), and IK Healthcare Merger Limited ( Merger Sub ), a wholly-owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into the Issuer (the Merger ) with the Issuer continuing as the surviving company and a wholly-owned subsidiary of Parent at the effective time of the Merger. As previously disclosed by the Issuer in its report on Form 6-K filed with the SEC on August 20, 2018, prior to the extraordinary general meeting of the Issuer held on August 20, 2018, the Issuer received notices of objection under Section 238(2) of the Cayman Islands Companies Law from holders of the Issuer s Class A common shares representing, collectively, approximately 30.49% of the total issued and outstanding shares of the Issuer. As a result, the closing condition under Section 7.02(e) of the Merger Agreement is not satisfied, and the Issuer has formally requested that Parent and Merger Sub waive this closing condition. If the Merger is not carried out and consummated, the New Mortgaged Shares of iKang Healthcare Group, Inc. will continue to be mortgaged pursuant to the New Share Mortgage to secure ShanghaiMed s obligations under New Facility Agreement. If the Merger is carried out and consummated, pursuant to the terms of the New Facility Agreement, ShanghaiMed may by written notice to Gopher request that the New Share Mortgage be released with effect from the date on which the Merger becomes effective ( Merger Effective Date ). Following such notice, Gopher will release the New Share Mortgage on the Merger Effective Date, subject to the satisfaction of certain conditions, including that Gopher has received an undated mortgage of shares executed by the parties thereto, to be dated on the Merger Effective Date, pursuant to which ShanghaiMed grants to Gopher a first-priority equitable mortgage of certain shares of Holdco in form and substance satisfactory to Gopher.

References to the Existing Share Mortgage and the New Share Mortgage in this Amendment No. 9 are qualified in their entirety by reference to the Existing Share Mortgage and the New Share Mortgage themselves, which are attached to Amendment No. 3 as Exhibit 7.8 and attached hereto as Exhibit 7.27, respectively, and are incorporated by reference as if set forth in their entirety.

#### Item 7. Material to be Filed as Exhibits.

Item 7 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

Exhibit

7.27 Description

Equitable Mortgage Over Shares in iKang Healthcare Group, Inc., dated as of August 24, 2018, by and between ShanghaiMed and Gopher

\*\*\*\*

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 4, 2018

LEE LIGANG ZHANG

By: /s/ LEE LIGANG ZHANG

Name: Lee Ligang Zhang

TIME INTELLIGENT FINANCE LIMITED

By: /s/ LEE LIGANG ZHANG

Name: Lee Ligang Zhang

Title: Director

SHANGHAIMED, INC.

By: /s/ LEE LIGANG ZHANG

Name: Lee Ligang Zhang

Title: Director

TMF (CAYMAN) LTD.

By: /s/ YEU CHI FAI and LIU KIN WAI

Name: YEU Chi Fai and LIU Kin Wai

Title: Authorized Signatories

TIME EVERGREEN COMPANY LIMITED

By: /s/ S.B. VANWALL LTD.

Name: S.B. Vanwall Ltd.

Title: Director

#### INDEX TO EXHIBITS

Exhibit Description 7.27

Equitable Mortgage Over Shares in iKang Healthcare Group, Inc., dated as of August 24, 2018, by and between ShanghaiMed, Inc. and Gopher Global Credit Fund II